Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Fujian South Pharmaceutical Co. Ltd
EIR
•Fujian South Pharmaceutical Co. Ltd•October 11, 2024

Fujian South Pharmaceutical Co. Ltd – FDA EIR, Oct 11, 2024

Record Details

An FDA pre-surveillance inspection of Fujian South Pharmaceutical Co. Ltd, located in Mingxi County, China, was conducted from October 7-11, 2024. This inspection, carried out under eNSpect PAC codes 46832 and 56002F and guided by ICH Q7 and Good Manufacturing Practices (GMPs), focused on the company’s Active Pharmaceutical Ingredient (API) manufacturing operations. The inspection aimed to evaluate readiness for commercial manufacturing, conformance to submissions, data integrity, and commitment to quality. A significant finding was that the inspection concluded with no issuance of an FDA Form 483, indicating no new regulatory violations were observed. The report highlighted that all five observations from a previous FDA inspection in September 2015, which concerned laboratory stability testing, method verification, equipment calibration, and equipment qualification, were thoroughly verified as corrected during this visit. Fujian South Pharmaceutical Co. Ltd demonstrated established quality, production, facilities and equipment, laboratory control, materials, and packaging and labeling systems. The review of original records, manufacturing processes, and quality controls revealed accuracy, completeness, and adherence to regulatory expectations. Management's active role in ensuring product quality and fostering a culture of integrity was also noted. This positive outcome reflects the company's commitment to maintaining high pharmaceutical manufacturing standards without requiring any new immediate actions from the FDA.

Company
Fujian South Pharmaceutical Co. Ltd
Inspection date
October 11, 2024
Product type
drugs
Office
Office of Inspections and Investigations
Person
  • Michael A. Charles (Investigator)
View Company Profile

ID · 49f12bde-f022-48d9-8fcb-000e092157c3

Violation Codes3
FD&C Act 501(a)(2)(B)21 CFR 820.19821 CFR 211

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fujian South Pharmaceutical Co. Ltd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.